| Sep 19 |
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
|
| Sep 12 |
Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc
|
| Sep 10 |
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive...
|
| Aug 22 |
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
|
| Aug 20 |
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
|
| Aug 14 |
Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session
|
| Aug 14 |
Acelyrin, Inc. (SLRN) Q2 2024 Earnings Call Transcript
|
| Aug 14 |
Acelyrin, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 13 |
Acelyrin reports positive phase 3 data on izokibep for inflammatory skin disorder
|
| Aug 13 |
Acelyrin GAAP EPS of -$0.86 misses by $0.17
|
